Guidelines for therapy of autoimmune liver disease

Seminars in Liver Disease

Volumn 27, Issue 2, 2007, Pages 214-226

  Ishibashi, Hiromi ^a,b   Komori, Atsumasa ^a,b   Shimoda, Shinji ^c   Gershwin, M Eric ^d  

^a NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoimmune hepatitis; Guideline; Overlapping syndrome; Primary biliary cirrhosis; Primary sclerosing cholangitis; Treatment

Indexed keywords

AZATHIOPRINE; BEZAFIBRATE; CORTICOSTEROID; CYCLOSPORIN; FENOFIBRATE; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; TACROLIMUS; URSODEOXYCHOLIC ACID;

ACNE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; AVASCULAR NECROSIS; BONE MARROW SUPPRESSION; CANCER SCREENING; CATARACT; CHOLESTASIS; CHOLESTATIC HEPATITIS; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; EPIGASTRIC PAIN; GASTRODUODENAL ULCER; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; MENTAL DISEASE; MOON FACE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSTEOPOROSIS; PANCREATITIS; PORTAL HYPERTENSION; PRACTICE GUIDELINE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PRURITUS; PSYCHOSIS; RASH; REVIEW; SJOEGREN SYNDROME; STOMACH PAIN; TREATMENT FAILURE; TREATMENT INDICATION; TUBERCULOSIS; VEIN OCCLUSION; VOMITING;

EID: 34249912673     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979472     Document Type: Review

References (84)

1. Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006;354:54-66
2. Krawitt EL, Bonis PAL. Treatment of autoimmune hepatitis. Available at: www.uptodate.com. Accessed October 2006
3. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996;110:848-857
4. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002;36:479-497
5. Mackay IR. Chronic hepatitis: effect of prolonged suppressive treatment and comparison of azathioprine with prednisolone. Q J Med 1968;37:379-392
6. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973;1:735-737
7. Summerskill WH, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975;16:876-883
8. Manns MP, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology 2006;43(suppl 1):S132-S144
9. Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease (CALD): correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 1981;80:687-692
10. Nakamura K, Yoneda M, Yokohama S, et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Heparol 1998;13:490-495
11. Kanzler S, Gerken G, Lohr H, et al. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol 2001;34:354-355
12. Czaja AJ, Ludwig J, Baggenstoss AH, Wolf A. Corticosreroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis. N Engl J Med 1981;304:5-9
13. Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984;4:622-627
14. Czaja AJ. Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology 1990;11:1044-1049
15. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995;333:958-963
16. Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol 2001;96:1224-1231
17. Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002;35:890-897
18. Schalm SW, Ammon HV, Summerskill WH. Failure of customary treatment in chronic active liver disease: causes and management. Ann Clin Res 1976;8:221-227
19. Pratt DS, Flavin DP, Kaplan MM. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology 1996;110:271-274
20. Fernandes NF, Redeker AG, Vierling JM, et al. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999;94:241-248
21. Aqel BA, Machicao V, Rosser B, et al. Efficacy of tacrolimus in the treatment of steroid refactory autoimmune hepatitis. J Clin Gastroenterol 2004;38:805-809
22. Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998;29:990-993
23. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000;33:371-375
24. Feld JJ, Dinh H, Arenovich T, et al. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005;42:53-62
25. Miyake T, Miyaoka H, Abe M, et al. Clinical characteristics of autoimmune hepatitis in older aged patients. Hepatol Res 2006;36:139-142
26. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971;40:159-185
27. Roberts SK, Therneau T, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996;110:848-857
28. Dufour JF, De Lellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997;127:981-985
29. Malekzadeh R, Mohamadnejad M, Nasseri-Moghaddam S, et al. Reversibility of cirrhosis in autoimmune hepatitis. Am J Med 2004;117:125-129
30. Sanchez-Urdazpal L, Czaja AJ, van Hoek B, et al. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 1992;15:215-221
31. Ratziu V, Samuel D, Sebagh M, et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol 1999;30:131-141
32. Gonzalez-Koch A, Czaja AJ, Carpenter HA, et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 2001;7:302-310
33. Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984;4:622-627
34. Ferrero S, Ragni N. Inflammatory bowel disease: management issues during pregnancy. Arch Gynecol Obstet 2004;270:79-85
35. Park SZ, Nagorney DM, Czaja AJ. Hepatocellular carcinoma in autoimmune hepatitis. Dig Dis Sci 2000;45:1944-1948
36. Maggiore G, Veber F, Bernard O, et al. Autoimmune hepatitis associated with anti-actin antibodies in children and adolescents. J Pediatr Gastroenterol Nutr 1993;17:376-381
37. Gregorio GV, Portmann B, Reid F, et al. Autoimmune hepatitis in childhood: a 20 year survey. Hepatology 1997;25:541-547
38. Mieli-Vergani G, Vergani D. Autoimmune hepatitis in children. Clin Liver Dis 2002;6:623-634
39. Alvarez F, Ciocca M, Canero-Velasco C, et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999;30:222-227
40. Steven MM, Buckley JD, Mackay IR. Pregnancy in chronic active hepatitis. Q J Med 1979;48:519-531
41. Heneghan MA, Norris SM, O'Grady JG, et al. Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001;48:97-102
42. Schramm C, Herkel J, Beuers U, et al. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 2006;101:556-560
43. Bellary S, Schiano T, Hartman G, et al. Chronic hepatitis with combined features of autoimmune chronic hepatitis and chronic hepatitis C: favorable response to prednisone and azathioprine. Ann Intern Med 1995;123:32-34
44. Nakamura K, Yoneda M, Takamoto S, et al. Effect of ursodeoxycholic acid on autoimmune-associated chronic hepatitis C. J Gastroenterol Hepatol 1999;14:413-418
45. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005;353:1261-1273
46. Kaplan MM. Overview of the treatment of primary biliary cirrhosis. Available at: www.uptodate.com. Accessed October 2006
47. Gershwin ME, Mackay IR. Primary biliary cirrhosis: paradigm or paradox for autoimmunity. Gastroenterology 1991;100:822-833
48. Aoki CA, Roifman CM, Lian ZX, et al. IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. J Autoimmun 2006;27:50-53
49. Selmi C, Invernizzi P, Keeffe EB, et al. Epidemiology and pathogenesis of primary biliary cirrhosis. J Clin Gastroenterol 2004;38:264-271
50. Rieger R, Leung PS, Jeddeloh MR, et al. Identification of 2-nonynoic acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis. J Autoimmun 2006;27:7-16
51. Heathcote EJ. AASLD guideline: management of primary biliary cirrhosis. Hepatology 2000;31:1005-1013
52. Poupon RE, Poupon R, Balkau B, The UDCA-PBC Study Group. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994;330:1342-1347
53. Lindor KD, Dickson ER, Baldus WP, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994;106:1284-1290
54. Combes B, Carithers RL, Maddrey WC, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995;22:759-766
55. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113:884-890
56. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006;130:715-720
57. Nakai S, Masaki T, Kurokohchi K, et al. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am J Gastroenterol 2000;95:326-327
58. Kurihara T, Maeda A, Shigemoto M, et al. Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy. Am J Gastroenterol 2002;97:212-214
59. Yano K, Kato H, Morita S, et al. Is bezafibrate histologically effective for primary biliary cirrhosis? Am J Gastroenterol 2002;97:1075-1077
60. Dohmen K, Mizuta T, Nakamura M, Shimohashi N, Ishibashi H, Yamamoto K. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol 2004;10:894-898
61. Sakauchi F, Mori M, Zeniya M, Toda G. A cross-sectional study of primary biliary cirrhosis in Japan: utilization of clinical data when patients applied to receive public financial aid. J Epidemiol 2005;15:24-28
62. Elta GH, Sepersky RA, Goldberg MJ, et al. Increased incidence of hypothyroidism in primary biliary cirrhosis. Dig Dis Sci 1983;28:971-975
63. Sbibuya A, Tanaka K, Miyakawa H, et al. Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis. Hepatology 2002;35:1172-1178
64. Jones DEJ, Metcalf JV, Collier JD, Bassendine MF, James OFW. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology 1997;26:1138-1142
65. Nijhawan PK, Therneau TM, Dickson ER, Boynton J, Lindor K.D. Incidence of cancer in primary biliary cirrhosis: the Mayo experience. Hepatology 1999;29:1396-1396-1398
66. Markus BH, Dickson E, Grambsch P, et al. Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med 1989;320:1709-1713
67. Poison RJ, Portmann B, Neuberger J, Calne RY, Williams R. Evidence for disease recurrence after liver transplantation for primary biliary cirrhosis: clinical and histologic follow-up studies. Gastroenterology 1989;97:715-725
68. Balan V, Batts KP, Porayko MK, Krom RAF, Ludwig J, Wiesner RH. Histological evidence for recurrence of primary biliary cirrhosis after liver transplantation. Hepatology 1993;18:1392-1398
69. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989;10:1-7
70. Kim WR, Wiesner RH, Therneau TM, et al. Optimal timing of liver transplantation for primary biliary cirrhosis. Hepatology 1998;28:33-38
71. Nakamura M, Shimizu-Yoshida Y, Takii Y, et al. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. J Hepatol 2005;42:386-392
72. Nakamura M, Kondo H, Mori T, et al. Anti-gp210 and anticentromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007;45:118-127
73. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998;28:360-365
74. Boberg KM, Fausa O, Haaland T, et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 1996;23:1369-1376
75. Poupon R, Chazouilleres O, Corpechot C, Chretien Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 2006:44:85-90
76. Czaja AT. The variant forms of autoimmune hepatitis. Ann Intern Med 1996;125:588-598
77. Ben-Ari Z, Dhillon AP, Sherlock S. Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis. Hepatology 1993;18:10-15
78. Colombato LA, Alvarez F, Cote J, et al. Autoimmune cholangiopathy: the result of consecutive primary biliary cirrhosis and autoimmune hepatitis. Gastroenterology 1994;107:1839-1843
79. Goodman ZD, McNally PR, Davis DR, et al. Autoimmune cholangitis - a variant of primary biliary cirrhosis: clinicopathologic and serologic correlations in 200 cases. Dig Dis Sci 1995;40:1232-1242
80. Chazouillères O, Wendum D, Serfaty L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998;28:296-301
81. Joshi S, Cauch-Dudek K, Wanless JR, et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology 2002;35:409-413
82. LaRusso NF, Shneider BL, Black D, et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology 2006;44:746-764
83. Wiesner RH, Porayko MK, Hay JE, et al. ER liver transplantation for primary sclerosing cholangitis: impact of risk factors on outcome. Liver Transpl Surg 1996;2(suppl 1):99-108
84. Floreani A, Rizzotto ER, Ferrara F, et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005;100:1516-1522